Fulcrum Therapeutics (FULC) Return on Sales [ROS] (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Return on Sales [ROS] of -105.97% for Q2 2025, down 171.58 percentage points from 65.62% a year earlier.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) Return on Sales [ROS] (2018 - 2026) Analysis & Trends
For FY2024, Fulcrum Therapeutics posted Return on Sales [ROS] of -27.37%, up 3917.87 percentage points from FY2023.
- Return on Sales [ROS] has a four-year change of +784.27 percentage points (FY2020 to FY2024).
- By year, Return on Sales [ROS] came in at -3945.24% in FY2023 (-2170.39 pp), -1774.85% in FY2022 (-1351.88 pp), -422.97% in FY2021 (+388.67 pp) and -811.64% in FY2020.
- The Q2 2025 figure ranks as the lowest quarterly Return on Sales [ROS] since Q1 2024.
- Year over year, Return on Sales [ROS] gained in five of the last seven quarters, with an average year-over-year change of +2008.51 percentage points.
- The high point for year-over-year Return on Sales [ROS] in five years was Q1 2024 (a gain of 4986.80 percentage points); the low point was Q1 2023 (a drop of 8468.18 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 34.46% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 24.35% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 36.01% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 30.74% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 29.12% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 35.79% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 41.71% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 32.98% |
| 10 | Fulcrum Therapeutics | 283.78 Mn | -59.56 Mn | - | -936.12% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -936.12% |
| Mar 31, 2026 | -673.32% |
| Dec 31, 2025 | -3,084.75% |
| Sep 30, 2025 | -2,965.98% |
| Jun 30, 2025 | -3,084.90% |
| Mar 31, 2025 | -742.47% |
| Dec 31, 2024 | -27.37% |
| Sep 30, 2024 | -37.66% |
| Jun 30, 2024 | 65.62% |
| Mar 31, 2024 | -4,484.38% |
| Dec 31, 2023 | -3,213.78% |
| Sep 30, 2023 | -3,615.28% |
| Jun 30, 2023 | -3,101.36% |
| Mar 31, 2023 | -9,471.19% |
| Dec 31, 2022 | -4,083.65% |
| Sep 30, 2022 | -2,058.75% |
| Jun 30, 2022 | -1,819.08% |
| Mar 31, 2022 | -1,003.01% |
| Dec 31, 2021 | -465.78% |
| Sep 30, 2021 | -420.87% |
API Access
Fulcrum Therapeutics Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=FULC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "FULC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=FULC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();